INOVIO reveals pricing details for $25 million public offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy INO?
Source: SeekingAlpha
Public Offering Announcement: INOVIO Pharmaceuticals has priced an underwritten public offering of 13.15 million shares at $1.90 per share, with all shares being sold by the company.
Closing Date and Additional Options: The offering is expected to close around November 12, and underwriters have a 30-day option to purchase an additional 1,973,700 shares at the same price.
Expected Proceeds: The gross proceeds from the offering are anticipated to be approximately $25 million.
Market Reaction: Following the announcement, INO's stock dropped 6% in premarket trading, with shares priced at $2.005.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.680
Low
3.00
Averages
7.33
High
13.00
Current: 1.680
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INOVIO ANTICIPATES START OF COMBINATION THERAPY DOSING TRIAL IN SECOND HALF OF 2026
- Trial Announcement: The INOVIO dosing in combination therapy trial is expected to begin in the second half of 2026.
- Focus of the Trial: This trial will explore the efficacy of INOVIO's treatment in combination with other therapies.
See More
INOVIO AND AKESO PARTNER TO FURTHER DEVELOPMENT OF INNOVATIVE COMBINATION TREATMENT FOR GLIOBLASTOMA (GBM)
Announcement of Clinical Collaboration: Inovio and Akes have announced a clinical collaboration aimed at advancing a novel combination therapy for glioblastoma (GBM).
Focus on Glioblastoma Treatment: The collaboration seeks to enhance treatment options for glioblastoma, a highly aggressive form of brain cancer.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the implications for the INO-3107 Biologics License Application, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel to avoid inexperienced intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
INOVIO ANTICIPATES START OF COMBINATION THERAPY DOSING TRIAL IN SECOND HALF OF 2026
- Trial Announcement: The INOVIO dosing in combination therapy trial is expected to begin in the second half of 2026.
- Focus of the Trial: This trial will explore the efficacy of INOVIO's treatment in combination with other therapies.
See More
INOVIO AND AKESO PARTNER TO FURTHER DEVELOPMENT OF INNOVATIVE COMBINATION TREATMENT FOR GLIOBLASTOMA (GBM)
Announcement of Clinical Collaboration: Inovio and Akes have announced a clinical collaboration aimed at advancing a novel combination therapy for glioblastoma (GBM).
Focus on Glioblastoma Treatment: The collaboration seeks to enhance treatment options for glioblastoma, a highly aggressive form of brain cancer.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the implications for the INO-3107 Biologics License Application, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel to avoid inexperienced intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
